Gut Microbiota Research & Practice is a section dedicated to promoting knowledge-sharing and debate among researchers, scientists and healthcare professionals. You will find a selection of discussions about articles from scientific literature as well as other content including interviews with experts, event reports, and special publications.
by Stefan Jellbauer
An interesting translational symposium of the American Association of Gastroenterology (AGA) at this year’s Digestive Disease Week (DDW) in Washington, D.C., was entitled, “Gut Microbiome and Clinical Outcomes in Pediatrics”.
by Kristina Campbell
Results of a research collaboration between Harvard and Danone, released today, show that an 'underrated' species of bacteria, Lactococcus lactis CNCM I-1631, conferred beneficial effects in mouse models of inflammation.
by GMFH Editing Team
Dr. Justin Sonnenburg, of Stanford University, is carrying out exciting research in the area of host-microbiota interactions. He is also the co-author of a popular book called "The Good Gut".
The higher rates of colon cancer in Americans of African origin compared to South Africans are usually attributed to diets containing more animal protein and fat and less fibre.
Dr. Liping Zhao, of Shanghai Jiao Tong University, is at the cutting edge of research on how the gut microbiota influence obesity.
by GMFH Editing Team
Dr. Patrice Cani, from Catholic University of Louvain, is a leading researcher in the area of gut microbiota and metabolic disorders. He serves on the Gut Microbiota for Health board of experts.
Dysbiosis -- an abnormal gut microbiota -- is associated with several diseases, including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
by Paul Enck
This interesting and well-balanced review examined how long-term and short-term changes in dietary fibre intake affect the microbiome and metabolome.
Dr. Premysl Bercik is a gastroenterologist, researcher, and Associate Professor in the Division of Gastroenterology at McMaster University in Canada.
by GMFH Editing Team
Inflammatory bowel diseases (IBD) are characterized by low proportions of Faecalibacterium prausnitzii in the gut microbiome. F. prausnitzii is a commensal intestinal bacterium known for its anti-inflammatory activity, although its mechanisms of action are still unknown.
